Table 6.
Excessive fibrinolysis (e. g. liver transplantation, medication induced) |
Adjuvant as hemostatic agent, in hemophilia and von Willebrand disease (e. g. dentistry, not in renal bleeding!) |
Mucosal bleeding (topicala, oral, intravenous), exception: bleeding of the upper urinary tract |
Primary and adjuvant in hereditary thrombopathies/thrombopenia [102, 103] |
PAI 1 deficiency, α2-plasmin inhibitor deficiency, hereditary telangiectasia |
Adjuvant in:
acquired thrombocytopenia cardiac surgery bypass surgery |
aTopical use: TXA (solution for injection) is locally applied without dilution or diluted with NaCl 0.9%; when applied in the mouth the swallowed amount should be added to the total dosage. The topical application is not included in the SmPC